GlassScriptPhysician profile
Nicholas J Sutton
NPI 1699148726
$661.06
in general payments reported to CMS, 2019-2025
15 companies · $246 in 2025
The $246 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $91.15 · 2023: $15.57 · 2024: $309 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $569.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $92.23 | 2024 | Auvelity |
| Orexo US, INC. | $75.77 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $75.52 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Indivior INC. | $66.34 | 2024-2025 | Sublocade |
| Neurocrine Biosciences, INC. | $66.33 | 2024-2025 | Ingrezza |
| Braeburn INC. | $56.32 | 2024-2025 | Brixadi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.18 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $38.54 | 2025 | Rexulti, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $34.93 | 2025 | Invega Sustenna |
| Tris Pharma INC | $23.13 | 2024 | Dyanavel Xr |
| Alkermes, INC. | $18.62 | 2025 | Vivitrol |
| Lundbeck LLC | $18.53 | 2024 | Rexulti |
| Collegium Pharmaceutical, INC. | $17.30 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $16.94 | 2024 | Qelbree |
| Abbvie INC. | $15.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Sutton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.